buying-guideJune 11, 2026·11 min read

Buy Noopept: Price, COA & Cost Per Week

Only 1 vetted Noopept source right now: $19.99 a vial, $0.00/mg. Codes save up to 10%. COA status and real cost per week.

Save

Noopept buying guide

Noopept (INN omberacetam, CAS 157115-85-0, also listed under the development codes GVS-111 and SGS-111) is a synthetic dipeptide-derived nootropic — the ethyl ester of N-phenylacetyl-L-prolylglycine — sold as a research chemical in powder and capsule forms. It stands apart from most research nootropics for one reason that matters to a buyer: it is one of the few with actual published human clinical data, and it has a dose that was actually used in trials. This guide is built for sourcing decisions: what forms exist, what a Certificate of Analysis should show, what the trial-derived dose figure means, and the honest evidence context behind the marketing.

A second distinction worth setting up front: Noopept is an orally active small molecule, not an injectable peptide. There is no reconstitution, no bacteriostatic water, and no injection. That changes how it is packaged and how a buyer should evaluate a listing — the handling language used for injectable peptides does not apply here.

Research-context information only. Noopept is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Noopept is sold strictly as a research chemical — research use only (RUO), labeled not for human consumption. It is sold by Swiss Chems, a recommended vendor on this site as of 2026-06-11. This guide is not a ranked vendor list; for current offers, see the Best Noopept Vendors comparison. The purpose here is to teach how to evaluate any Noopept listing yourself, with extra weight on the evidence context most competitor pages leave out.

Understanding Noopept Pricing

Noopept is sold as a research chemical — not a supplement, not a compounded medicine, and not an FDA- or EMA-approved drug in Western markets. (It is a registered medicine in Russia for cognitive disorders of vascular and post-traumatic origin, but that human-grade Russian pharmaceutical product is not what Western research-chemical vendors sell.) That distinction shapes pricing: there is no Western pharmacopeial monograph and no regulatory floor on quality, so price tracks form factor, advertised purity, and how much active material is in the package.

Two forms dominate the market:

Form Typical packaging What you're paying for Notes
Research powder Bulk powder by mass Raw research material Most flexible; the buyer handles measurement. No solvent or reconstitution — it is orally active
Capsules Commonly cited ~20 mg per capsule Pre-measured convenience Higher cost per mg than bulk powder; the convenience is the premium. Verify the live per-cap amount — SKUs move

The pattern across research-chemical pricing is consistent: bulk powder carries the lowest cost per mg, while pre-measured capsules add a convenience premium. Noopept is unusually potent by dose — it is active at tens of milligrams, whereas the older racetam piracetam is dosed in grams. That "roughly 1000x more potent than piracetam" line refers to potency by dose, not to being 1000x more effective. The practical buying consequence is that a given mass of Noopept powder represents a large number of trial-scale 10-20 mg units, so per-mg comparison of the raw material is the cleaner way to compare listings. For current vendor-specific pricing, see the Best Noopept Vendors page.

A note on the dose figure, because it affects how a buyer reads "cost per dose." Unlike many research nootropics, Noopept has a clinically studied dose: Russian trials used 20 mg/day (10 mg twice daily) in mild cognitive impairment and stroke populations (PMID 18697252, 22500312). Community and vendor sources most commonly cite a wider 10-30 mg/day, usually split into 2-3 small doses, with new users often starting around 10 mg. The 20 mg/day figure is trial-derived; the wider spread above it is community/vendor-derived, not trial-validated. There is a real dose here — it is just important to keep the trial figure separate from the anecdotal range.

How to Verify Noopept Quality

Noopept COA and HPLC verification

With no Western regulatory oversight and no standardized product, the Certificate of Analysis (COA) is the most objective signal a buyer has. Noopept is a small modified dipeptide ester (chemical name N-phenylacetyl-L-prolylglycine ethyl ester, CAS 157115-85-0). Synthesis impurities, incomplete reactions, and mislabeled material are real risks in the research-chemical market, and a COA is what distinguishes a tested batch from an unverified one.

What a COA Should Include

Identity confirmation

  • An identity test (e.g. mass spectrometry) confirming the compound matches omberacetam / CAS 157115-85-0
  • Confirmation that the material is Noopept specifically, not a generic "racetam" assay

Purity testing

  • HPLC purity — reputable listings commonly claim ~98% or higher
  • An HPLC chromatogram showing a single dominant peak, not a cluster of unresolved peaks

Contamination testing

  • Residual solvent analysis where the supplier provides it
  • Heavy metals screening where the supplier provides it

How to Verify a COA Is Legitimate

  1. Match the batch. The lot/batch number on the COA should match the number on the container you receive — not just "a" COA for the product line.
  2. Check the date. A COA should be recent and tied to the production run being purchased, not a years-old generic certificate.
  3. Identify the lab. Independent third-party lab COAs carry more weight than in-house-only documents. A named lab that can be looked up is a better signal than an unsigned PDF.
  4. Read the chromatogram, not just the headline number. A "98%" claim with no attached HPLC trace is just a number. The trace should show one dominant peak.
  5. Confirm the compound identity. The COA should test for Noopept specifically (correct mass, correct CAS), not a generic assay.

Red Flags to Avoid

  • No COA available, or a COA that won't load / is image-only with no lab name
  • Batch numbers that don't match between COA and container
  • Purity claimed with no supporting HPLC chromatogram
  • Marketing that presents a "long half-life" as established fact — rat pharmacokinetic work found Noopept and its active metabolite clear quickly (the metabolite's terminal half-life is on the order of minutes, not days, PMID 30378564), so durable-effect claims are attributed to downstream signaling, not a long-circulating compound
  • Human dosing instructions or therapeutic claims on the listing — a tell that the seller is ignoring RUO rules
  • Injectable Noopept listings or reconstitution instructions — Noopept is orally active and is not an injectable peptide; that framing is a red flag

A clean COA verifies that the powder is what the label says. It does not verify that Noopept is safe for long-term use in healthy people — no such database exists, which is an important thing for a buyer to understand even given the compound's comparatively strong evidence base.

CategoryCognitive & Neuro Peptides
Noopept research vial
Where to buy Noopept
One verified, COA-tested Noopept source
The verified, COA-tested source we track for Noopept — shipped with a certificate of analysis. Research use only.
✓ COA verified✓ $0.83/mg✓ Swiss Chems
Save 10%THEPEPTIDECATALOGat checkout
Buy at Swiss Chems — $24.99
30mg · sold research-use-only · we may earn a commission

Choosing the Right Vial Size

Noopept powder and capsule forms

Because Noopept is sold as powder or capsules rather than reconstituted vials, the "size" decision is really a form-and-quantity decision. Each option trades off cost, convenience, and handling. None of this is a recommendation about route or amount — it is a comparison of practical attributes only.

Form Cost per mg Convenience Buyer handling
Powder (bulk) Lowest Lowest — buyer measures everything Requires an accurate milligram scale; no solvent prep (orally active)
Capsules Higher Highest — pre-measured Fixed per-capsule amount (often cited ~20 mg); no measuring

The handling consideration that separates Noopept from larger powder nootropics is its potency by dose. Trial-scale units are 10-20 mg, which is a small mass — measuring it accurately needs a scale with milligram resolution, not a kitchen scale. That is the main argument community sources make for capsules over bulk powder: pre-measured units remove the small-mass weighing problem. The trade-off is the per-mg premium and the fixed per-capsule amount.

On route: oral is standard and matches the studied route — oral antiamnesic activity was established in rats at 0.5-10 mg/kg (PMID 11782792). Some community sources report sublingual use anecdotally, but no human pharmacokinetic data supports a sublingual advantage, and there is no injectable route. Community sources also commonly describe cycling (several weeks on, then a break) and pairing Noopept with a choline source to manage anecdotally reported headache; no trial-defined cycling schedule exists, so that guidance is purely community convention.

The Evidence Context Every Buyer Should Know

This is where Noopept differs from most research nootropics a buyer might compare it against — and the difference cuts in Noopept's favor on some axes and against it on others. Both halves matter for a purchase decision.

Human data exists — which is rare. Noopept is one of the few research-chemical nootropics with published human trial data. A comparative trial reported Noopept at least comparable to piracetam — and in some asthenic/post-concussional subgroups significantly better — in patients with mild-to-moderate cognitive impairment of vascular and traumatic origin, with an MMSE shift reported from roughly 26 to 29 in the treated group over a 56-day course (Neznamov & Teleshova 2008, PMID 18697252). An open prospective stroke study (~60 patients, ~20 mg/day) reported improved cognition and "a high level of safety" (Amelin, Ilyukhina & Shmonin 2011, PMID 22500312). An EEG/clinical characterization described nonspecific cortical activation plus an anxiolytic component, more pronounced in vascular cases (Bochkarev et al. 2008, PMID 19008801).

But the human data is thin in rigor. The trials are Russian-language, mostly open-label or active-comparator (versus piracetam) rather than large placebo-controlled RCTs, largely from or near the originating research group, and conducted in disease populations (vascular/post-traumatic MCI, stroke) rather than healthy cognitive enhancement. The direction is positive; the rigor is limited. There is no large independent placebo-controlled efficacy base and essentially no Western RCT.

The preclinical signal is broad — and mechanistic. Noopept is rapidly metabolized to cycloprolylglycine, an endogenous cyclic dipeptide already present in mammalian brain; that metabolite showed dose-dependent anxiolytic activity in the elevated plus-maze, with the L-form active and the D-form inactive (Gudasheva et al. 2001, PMID 11550054). In an Alzheimer-type cellular model, Noopept pretreatment reduced apoptosis, lowered reactive oxygen species and intracellular calcium, and attenuated tau hyperphosphorylation at Ser396 (Ostrovskaya et al. 2014, PMID 25096780). These are mechanistic and preclinical — animal and cell models, not proven human mechanisms.

The honest caveat — and what it is not. Much of the mechanistic and clinical core comes from a single Russian originating group, and independent replication outside that group is limited. That is a depth-and-independence limitation. It is distinct from an integrity problem: no retractions, expressions of concern, or misconduct findings were identified for the Noopept literature during this research. A buyer should weigh that the evidence is real but concentrated, and that it sits in impaired populations rather than healthy users — not that it is compromised.

Vendor Evaluation Methodology

When weighing any Noopept listing, the same three-factor framework applies as for any research chemical — weighted price 40%, COA 30%, reputation 30%.

Price competitiveness (40%). Compare on cost per mg of raw material, not headline package price. Capsules carry a convenience premium over bulk powder; whether that premium is worth it is a handling preference (and, for a low-mass compound, a measurement-accuracy preference), not a quality difference.

COA and testing (30%). A current, batch-matched, third-party HPLC COA showing ~98%+ purity and correct identity (omberacetam, CAS 157115-85-0) is the floor. No COA, no purchase.

Reputation (30%). Look for consistent COA practices across batches, transparent lab sourcing, and listings that respect RUO framing rather than making human-use or therapeutic claims. A vendor that markets a "long half-life," presents the Russian human data as if it were a Western FDA approval, or attaches human dosing instructions is signaling weak editorial standards.

Shipping and Storage

What to Expect When an Order Arrives

Noopept powder typically arrives as a white crystalline-to-powder solid in a sealed container. Buyers commonly check container integrity (intact seal, no damage) and confirm the lot number matches the COA on arrival. Capsules arrive pre-measured in a sealed bottle. Because Noopept is orally active and sold as powder or capsules, there is no vial-reconstitution step and no bacteriostatic water involved.

Storage Guidelines

State Storage Notes
Powder Cool, dark, dry, sealed Standard research-chemical storage; keep away from moisture and light
Powder, longer holds Refrigerated, sealed and dry Cold storage preferred for extended storage
Capsules Cool, dry, sealed bottle Keep away from heat and humidity

Because no standardized stability data exists for Noopept across these forms in the Western research-chemical market, storage practices in the community follow general research-chemical conventions rather than compound-specific testing.

30ml bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
See why our bac water doesn't ruin peptides
30ml from $18.75 · Ships fast · Code thepeptidecatalog

Frequently Asked Questions

Is Noopept a peptide?
Not in the therapeutic sense. Noopept (INN omberacetam, CAS 157115-85-0) is a dipeptide-derived small-molecule nootropic — the ethyl ester of N-phenylacetyl-L-prolylglycine. It is orally active and not injected. It is grouped loosely with peptides because of its dipeptide backbone, but it behaves as a small molecule. There is no bacteriostatic-water reconstitution step.
What forms is Noopept sold in?
Two are common: bulk research powder and pre-measured oral capsules (commonly cited around 20 mg per capsule, though SKUs move). Both are sold for research use only (RUO), labeled not for human consumption. There is no injectable form — Noopept is an orally active small molecule.
What dose did the trials actually use?
Russian clinical trials in mild cognitive impairment and stroke used 20 mg per day (10 mg twice daily) for roughly 8 weeks or longer (PMID 18697252, 22500312). Community and vendor sources most often cite a wider 10-30 mg/day range; the portion above 20 mg/day is community-derived, not trial-validated. Noopept is not FDA- or EMA-approved in the West.
What purity should a Noopept COA show?
Reputable research-chemical COAs report HPLC purity, commonly claimed at ~98% or higher, alongside an identity test confirming the compound (mass matching omberacetam, CAS 157115-85-0). A single dominant HPLC peak and a recent batch date matched to your lot are the core signals. No COA verifies human safety — no long-term human safety database exists for healthy-user use.
Is the 'research credible' or were any Noopept papers retracted?
No retractions or misconduct findings were identified for the Noopept literature. The main limitation is that much of the work comes from a single Russian originating research group and from small, often open-label studies — a depth and independence caveat, not an integrity problem. Noopept is sold RUO and is not approved by Western regulators.
  • The COA-verification framework above applies to any research-chemical listing — the batch-match, dated-lab, single-peak HPLC checks transfer across compounds.
  • Readers comparing cognitive research compounds often look at the broader nootropic landscape, where most compounds lack the human trial data Noopept has — making evidence context as important as price when comparing listings.

References

  1. Neznamov GG, Teleshova ES. Zh Nevrol Psikhiatr Im S S Korsakova. 2008 — comparative trial of Noopept vs piracetam in mild-to-moderate cognitive impairment of vascular/traumatic origin; 20 mg/day regimen (PMID 18697252).
  2. Amelin AV, Ilyukhina AYu, Shmonin AA. Zh Nevrol Psikhiatr Im S S Korsakova. 2011 — open prospective stroke study, ~20 mg/day, improved cognition and high safety (PMID 22500312).
  3. Bochkarev VK, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008 — clinical + EEG characterization in post-traumatic/vascular MCI; activation plus anxiolytic effect (PMID 19008801).
  4. Ostrovskaya RU, et al. Bull Exp Biol Med. 2001 — GVS-111 (Noopept) retains antiamnesic activity after oral dosing in rats, 0.5-10 mg/kg (PMID 11782792).
  5. Ostrovskaya RU, Vakhitova YV, et al. J Biomed Sci. 2014 — AD cellular model (PC12/Aβ25-35): reduced apoptosis, ROS, Ca2+; attenuated tau-Ser396 phosphorylation (PMID 25096780).
  6. Gudasheva TA, Konstantinopol'skii MA, Ostrovskaya RU, Seredenin SB. Bull Exp Biol Med. 2001 — endogenous metabolite cycloprolylglycine: dose-dependent anxiolytic in the elevated plus-maze (PMID 11550054).

This article is for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, or prevent any condition. Noopept is sold for research use only and is not for human consumption. Consult a licensed healthcare provider before using any research compound.